Compare Amgen, Inc. (AMGN) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs PepsiCo, Inc. — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while PepsiCo, Inc. trades at $138.03 (market cap $187.51B). The key difference: Amgen, Inc. and PepsiCo, Inc. are close in size by market cap, and PepsiCo, Inc. pays the higher dividend (4.31%). Which is the better fit depends on your goals.
| AMGN | PEP | |
|---|---|---|
Market Cap | $196.12B | $187.51B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $170.44 |
52-Week Low | $271.18 | $133.81 |
Enterprise Value | $241.41B | $230.01B |
Dividend Yield | 2.77% | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PepsiCo (PEP) trades at $137.38, down 0.35% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 10.78% net income margin and 51.59% ROE, though revenue growth is modest. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while the company continues to beat earnings estimates, with Q3 2026 results pending.
The outlook is mixed: analyst consensus is a 'Hold' with a $159.27 price target, implying upside, but technical weakness and competitive pressures pose risks. Investment appeal lies in steady dividends and earnings beats, but margin pressures from pricing strategies and high debt levels require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
